You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

22 Items
Cancer Type: Hematologic, Lymphoma - T-cell, Rare Diseases     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
Dec 2017
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
Updated
Nov 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    iMAtinib - Adults with newly diagnosed Ph+ ALL, with specific criteria
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab-Trastuzumab - Unresectable Locally Recurrent or Metastatic - Breast Cancer
New Drug Funding Program
    Docetaxel - Metastatic Breast Cancer
Aug 2017
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
Jun 2019
Cancer Type: Lung, Neuroendocrine (Lung)     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
May 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - Treatment of metastatic renal cell carcinoma (mRCC) as second or third line therapy in patients
    previously treated for mRCC with a funded tyrosine kinase inhibitor (TKI), with specific criteria
Aug 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
Jun 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Jun 2019
Cancer Type: Gastrointestinal, Gastrointestinal Stromal Tumours, Sarcoma, GIST     
Intent: Adjuvant
Funding:
Exceptional Access Program
    iMAtinib - Adjuvant Gastrointestinal Stromal Tumours, with specific criteria
Jun 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
ODB - General Benefit (with Therapeutic Notes)
    iMAtinib - For treatment of Ph+ CML in chronic phase, blast phase or accelerated phase, with specific criteria
Jun 2019